EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma

Friedrich Christian Franke, Adrian Damek, Jonas Steglich, Lars Kurch iD, Dirk Hasenclever, Thomas W Georgi, Walther Alexander Wohlgemuth, Christine Mauz-Körholz, Dieter Körholz, Regine Kluge, Judith Landman-Parker, William Hamish Wallace und 16 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Friedrich Christian Franke und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Diakoniekrankenhaus Halle, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Hodgkin Disease, Thymus Hyperplasia, Lymphoma, Thymus Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum.

Methods

After completion of CTX, we analyzed computed tomographies (CTs) and magnetic resonance images (MRIs) of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1 trial. In all patients with biopsy‐proven LR, an additional fluorodeoxyglucose (FDG)‐positron emission tomography (PET)‐CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated.

Results

After CTX, a significant volume increase of new or growing masses in the thymic space occurred in 133 of 291 patients. Without biopsy, only 98 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (33/34). All RTH patients (64/64) presented with isolated thymic growth.

Conclusion

Isolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, isolated thymic mass after CTX likely represents RTH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseThymus HyperplasiaLymphomaThymus NeoplasmsHumansChildNeoplasm Recurrence, LocalTomography, X-Ray ComputedPositron-Emission TomographyFluorodeoxyglucose F18Radiopharmaceuticals

Stichwörter der Autor:innen

18F-FDG-PETHodgkin lymphomacomputed tomographyrelapsethymusx-ray

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Diakoniekrankenhaus Halle, Halle (Saale), Germany.
  • Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany.
  • Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
  • Institute of Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
  • Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen, Germany.
  • Sorbonne Université/APHP hôpital Trousseau, Paris, France.

ORCID-Profile: Lars Kurch, Michaela Cepelova, Andishe Attarbaschi, Dietrich Stoevesandt

Zitieren

APA

Franke, F. C., Damek, A., Steglich, J., Kurch, L., Hasenclever, D., Georgi, T. W., Wohlgemuth, W. A., Mauz-Körholz, C., Körholz, D., Kluge, R., Landman-Parker, J., Wallace, W. H., Fosså, A., Vordermark, D., Karlen, J., Fernández-Teijeiro, A., Cepelova, M., Klekawka, T., Attarbaschi, A., …, & Stoevesandt, D. (2023). Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30421

Vancouver

Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, et al. Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30421

BibTeX
@article{Franke2023,
  author = {Franke, Friedrich Christian and Damek, Adrian and Steglich, Jonas and Kurch, Lars and Hasenclever, Dirk and Georgi, Thomas W and Wohlgemuth, Walther Alexander and Mauz-Körholz, Christine and Körholz, Dieter and Kluge, Regine and Landman-Parker, Judith and Wallace, William Hamish and Fosså, Alexander and Vordermark, Dirk and Karlen, Jonas and Fernández-Teijeiro, Ana and Cepelova, Michaela and Klekawka, Tomasz and Attarbaschi, Andishe and Ceppi, Francesco and Hraskova, Andrea and Uyttebroeck, Anne and Beishuizen, Auke and Dieckmann, Karin and Leblanc, Thierry and Moellers, Martin and Buerke, Boris and Stoevesandt, Dietrich},
  title = {Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30421}
}
Kostenlos starten →